Disparity in expression of protein kinase C α in human glioma versus glioma-derived primary cell lines: Therapeutic implications

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1797-1802

  Zellner, Anton ^a   Fetell, Michael R ^a   Bruce, Jeffrey N ^a   De Vivo, Darryl C ^a   O'Driscoll, Kevin R ^a,b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GLIOMA; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; HUMANS; ISOENZYMES; LACTONES; MACROLIDES; NEOPLASM PROTEINS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; TUMOR CELLS, CULTURED;

EID: 0031746727     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jaken, S. Protein kinase C isozymes and substrates. Curr. Opin. Cell Biol., 8: 168-173, 1996.
2. Weinstein, I. B. Nonmutagenic mechanisms in carcinogenesis: role of protein kinase C in signal transduction and growth control. Environ. Health Perspect., 93: 175-179, 1991.
3. Caponigro, F., French, R. C., and Kaye, S. B. Protein kinase C. A worthwhile target for anticancer drugs? Anti-Cancer Drugs, 8: 26-33, 1997.
4. Todo, T., Shitara, N., Nakamura, H., Takakura, K., and Ikeda, K. Immunohistochemical demonstration of protein kinase C isozymes in human brain tumors. Neurosurgery, 108: 11-16, 1991.
5. Benzil, D. L., Finkelstein, S. D., Epstein, M. H., and Finch, P. W. Expression pattern of α-protein kinase C in human astrocytomas indicates a role for malignant progression. Cancer Res., 52: 2951-2956, 1992.
6. Baltuch, G. H., Dooley, N. P., Villemure, J-G., and Yong, V. W. Protein kinase C and growth regulation of malignant gliomas. Can. J. Neurol. Sci., 22: 264-271, 1995.
7. Pollak, I. F., Rendall, M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., and Vertosick, F. T. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res., 50: 7134-7138, 1990.
8. Pollak, I. F., Kawecki, S., and Lazo, J. S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J. Neurosurg., 84: 1024-1032, 1996.
9. Begemann, M., Sharafadeen, A. K., Choi, Y. A., Kim, S., Christiansen K. M., Duigou, G., Mueller, M., Schieren, I., Ghosh, S., Fabbro, D., Lampen, N. M., Heitjan, D. F., Schiff, P. B., Bruce, J. N., and Weinstein, I. B. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin. Cancer Res., 2: 1017-1030, 1996.
10. Ahmad, S., Mineta, T., Martuza, R. L., and Glazer, R. I. Antisense expression of protein kinase Cα inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery, 35: 904-909, 1994.
11. Yazaki, T., Ahmad, S., Chahlavi, A., Zylber-Katz, E., Dean N. M., Rabkin, S. D., Martuza, R. L., and Glazer, R. I. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol., 50: 236-242, 1996.
12. Xiao, H., Goldthwait. D. A., and Mapstone, T. The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC α, γ. ∈. and ζ. J. Neurosurg., 81: 734-740, 1994.
13. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
14. Varterasian. M., Eilender, D., Mohammad. R., Chen, B., Hulburd, K., Rodriguez, D., Pluda, J., Valdivieso, M., and Al-Katib, A. Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Proc. Am. Soc. Clin. Oncol., 15: 481, 1996.
15. Kraft, A. S., Baker, V. V., and May, W. S. Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene, 1: 11-118, 1987.
16. Kennedy, J. M., Prestigiacomo, L. A., Tyler, G., May, S., and Davidson, N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res., 52: 1278-1283, 1992.
17. Jalava, A., Lintunen, M., and Heikkilä, J. Protein kinase C-α but not protein kinase C-∈ is differentially down-regulated by bryostatin 1 and tetradecanoyl phorbol 13-acetate in SH-SY5Y human neuroblastoma cells. Biochem. Biophys. Res. Commun., 191: 472-478, 1993.
18. Szallasi, Z., Denning, M. F., Smith, C. B., Dlugosz, A. A., Yuspa, S. H., Pettit, G. R., and Blumberg, P. M. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol., 46: 840-850, 1994.
19. Johannes, F-J., Prestle, J., Eis, S., Oberhagemann, P., and Pflzenmayer, K. PKC μ is a novel, atypical member of the protein kinase C family. J. Biol. Chem., 25: 6140-6148, 1994.
20. Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S-E., Kern, T. S., Ballas, L. M., Heath, W. F., Stramm, L. E., Feener, E. P., and King, G. L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science (Washington DC), 272: 728-731, 1996.
21. Blobe, G. C., Obeid, L. M., and Hannun, Y. A. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev., 13: 411-431, 1994.